What did the March 2, 2026 NTLA analyst rating from Bank of America say?

Bank of America on March 2, 2026 maintained a Neutral rating on Intellia (NTLA) and raised its price target to $19, citing clinical timelines and cash runway as key determinants for future upside.

How should investors interpret the NTLA analyst rating and $19 price target?

The NTLA analyst rating of Neutral with a $19 target indicates in-line performance expectations; investors should wait for mid-2026 clinical readouts before increasing exposure.

Does Meyka AI provide a grade for NTLA alongside analyst notes?

Yes. Meyka AI rates NTLA with a grade of B, combining benchmark, sector, growth, metrics, and analyst consensus; grades are not guarantees and are not investment advice.

Where can I read the Bank of America note and Intellia’s recent results?

The Bank of America comment is available via StreetInsider and Intellia’s Q4 2025 results are published through the company press release and Seeking Alpha PR, linked in our coverage for reference.

Analyst Ratings

BofA Maintains NTLA Neutral for Intellia Therapeutics on Mar 2, 2026

ByDanny Kontos March 3, 2026March 3, 2026

Bank of America Securities on March 2, 2026 maintained Neutral on Intellia Therapeutics (NTLA). This NTLA analyst rating included a price target increase to $19, signaling a cautious, valuation-focused view. The firm left its rating unchanged while raising the price target, a mixed signal for investors weighing near-term catalysts. The update coincided with a modest stock move of 2.25% ($0.34) following the note, illustrating immediate market sensitivity to price target tweaks.